Stephen K. Doberstein
2015
In 2015, Stephen K. Doberstein earned a total compensation of $1.2M as Senior Vice President and Chief Research and Development Officer at Nektar Therapeutics, a 46% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $198,300 |
|---|---|
| Option Awards | $127,085 |
| Salary | $495,800 |
| Stock Awards | $326,548 |
| Other | $13,054 |
| Total | $1,161,287 |
Doberstein received $495.8K in salary, accounting for 43% of the total pay in 2015.
Doberstein also received $198.3K in non-equity incentive plan, $127.1K in option awards, $326.5K in stock awards and $13.1K in other compensation.
Rankings
In 2015, Stephen K. Doberstein's compensation ranked 7,213th out of 13,638 executives tracked by ExecPay. In other words, Doberstein earned more than 47.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,213 out of 13,638 | 47th |
Division Manufacturing | 2,716 out of 5,190 | 48th |
Major group Chemicals And Allied Products | 973 out of 1,854 | 48th |
Industry group Drugs | 781 out of 1,528 | 49th |
Industry Pharmaceutical Preparations | 610 out of 1,182 | 48th |
Source: SEC filing on April 30, 2018.
Doberstein's colleagues
We found five more compensation records of executives who worked with Stephen K. Doberstein at Nektar Therapeutics in 2015.
2015
Howard Robin
Nektar Therapeutics
Chief Executive Officer
2015
John Nicholson
Nektar Therapeutics
Chief Financial Officer
2015
Gil Labrucherie
Nektar Therapeutics
General Counsel
2015
Maninder Hora
Nektar Therapeutics
Senior Vice President Pharmaceutical Development and Manufacturing Operations
2015
Ivan Gergel
Nektar Therapeutics